Ethris Announces Expansion of Leadership Team

-- Thomas Langenickel, M.D. appointed to Chief Medical Officer as lead program ETH42 advances toward clinical trials --

Munich, Germany, June 3, 2019Ethris GmbH, a leader in mRNA-based therapeutics with specific expertise in pulmonary disease, announced today the expansion of the company’s leadership team by the addition of Thomas Langenickel, M.D. in the role of Chief Medical Officer. Dr. Langenickel joins Ethris from Novartis AG, where he was Executive Director and Head of Respiratory Profiling within the Translational Medicine Group.

“Thomas has a wealth of experience in guiding novel programs from discovery research into clinical development and beyond,” stated Gita Dittmar, CEO of Ethris. “His leadership in translational medicine and deep experience in respiratory and cardiovascular disease indications make him a perfect fit for Ethris as we transition our lead program ETH42 for development activities.”

During his tenure at Novartis, Dr. Langenickel led translational medicine activities in respiratory, cardiovascular and metabolic diseases in the areas of clinical research and development, drug profiling and regulatory submissions. Prior, he held positions of increasing responsibility in Discovery Medicine at Bristol Myers Squibb. He obtained his M.D. and Ph.D. at Humboldt University of Berlin, trained in Clinical Pharmacology and Internal Medicine/Cardiology at the MaxDelbrück Center for Molecular Medicine and the Charité in Berlin, Germany and completed a postdoctoral fellowship at the National Heart, Lung and Blood Institute in Bethesda, USA.

“I am excited and very much looking forward to guide Ethris’ first drug candidate into development and to support further activities to build a pipeline of transcript therapies for pulmonary disorders,” commented Thomas Langenickel, new CMO of Ethris. “Within the very promising sector of mRNA-based therapeutics, Ethris stands out as a key player with unique technologies and capabilities to deliver these treatments into the respiratory system of the patient while also having significant potential in other indications.”

Ethris is developing a portfolio of SNIM® RNA therapies for genetic pulmonary diseases including respiratory ciliopathies. In addition, the company is researching SNIM® RNA therapies for treatment of asthma, chronic obstructive pulmonary disease, and idiopathic pulmonary fibrosis exclusively with AstraZeneca under a five-year collaboration.

About Ethris
Ethris has paved a new path from genes to therapeutic proteins using its proprietary, non-immunogenic messenger RNA technology platform to discover, design and develop innovative therapies. With more than a decade as an mRNA pioneer, we are a global leader in delivering stabilized mRNAs directly to the respiratory system via optimized formulation and nebulization technologies. We are rapidly advancing our pipeline of immuno-modulation and mRNA-based protein replacement therapies with the ultimate goal of improving patients’ lives.
For more information, visit

For Ethris, please contact:
Dr. Carsten Rudolph
+49 89 8955788 10
[email protected]

Media Relations
Dr. Jacob Verghese 
Trophic Communications 
+49 89 2388 7731
[email protected]